SCHEMBL17404868

SCHEMBL17404868

CC(C)(C)c1cnc(N2CCC3(CC2)CCN(C(C)(C)C)C3)nc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 6/20 0.36
▸ CYP2D6 P10635 5/20 0.36
▸ TSHR P16473 2/20 0.36
▸ MEN1 O00255 2/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ HSD17B10 Q99714 6/20 0.33
▸ ALDH1A1 P00352 4/20 0.33
▸ USP2 O75604 2/20 0.33
▸ HPGD P15428 1/20 0.33
▸ OGA O60502 1/20 0.32
▸ CYP1A2 P05177 2/20 0.32
▸ TDP1 Q9NUW8 1/20 0.32
▸ ALOX15 P16050 1/20 0.32
▸ CYP2C9 P11712 1/20 0.32
▸ GRIN2D O15399 1/20 0.31
▸ GRIN3B O60391 1/20 0.31
▸ CHRM2 P08172 1/20 0.31
▸ CHRM1 P11229 1/20 0.31
▸ OPRM1 P35372 1/20 0.31
▸ GRIN1 Q05586 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24827913 0.93 CYP3A4 (0.36) CYP3A4CYP2D6TSHRMEN1KMT2A
SCHEMBL13131096 0.89 USP2 (0.40) CYP3A4CYP2D6TSHRMEN1KMT2A
SCHEMBL24827851 0.87 HSD17B10 (0.42) CYP3A4CYP2D6TSHRMEN1KMT2A
SCHEMBL17404871 0.86 CYP2D6 (0.42) CYP3A4CYP2D6TSHRHSD17B10ALDH1A1
SCHEMBL11947825 0.83 CYP3A4 (0.53) CYP3A4CYP2D6TSHRMEN1KMT2A
SCHEMBL17404870 0.79 MEN1 (0.40) MEN1KMT2AHSD17B10OGATDP1
SCHEMBL24827849 0.78 OGA (0.36) CYP3A4CYP2D6TSHRMEN1KMT2A
SCHEMBL9906447 0.76 SMN1; SMN2 (0.42) CYP2D6TSHRMEN1KMT2AALDH1A1
SCHEMBL24827911 0.75 CYP3A4 (0.35) CYP3A4CYP2D6TSHRMEN1KMT2A
SCHEMBL13131034 0.74 MAPT (0.48) MEN1KMT2AALDH1A1HPGDCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9573956-B2 Compounds as dual inhibitors of phosphodiesterases and histone deacetylases FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) 2017-02-21 — — US disclosed
US-9573956-B2 Compounds as dual inhibitors of phosphodiesterases and histone deacetylases FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) 2017-02-21 — — US disclosed
US-20160002246-A1 NOVEL COMPOUNDS AS DUAL INHIBITORS OF PHOSPHODIESTERASES AND HISTONE DEACETYLASES FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) 2016-01-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160002246-A1 NOVEL COMPOUNDS AS DUAL INHIBITORS OF PHOSPHODIESTERASES AND HISTONE DEACETYLASES PDE1A, HDAC1, HDAC2 CYP3A4 2351/4885CYP2D6 2544/4885TSHR 3144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback